Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Lung Cancer (Amsterdam, Netherlands)|May 10, 2025
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancerVeronica Crespi, Marco Donatello Delcuratolo, Gabriele Minuti, et al.
Clinical Lung Cancer|August 24, 2022
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective StudyGiulia Mazzaschi, Fabiana Perrone, Roberta Minari, et al.
The Journal of Urology|July 22, 2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinomaMatteo Santoni, Alessandro Conti, Camillo Porta, et al.
Lung Cancer (Amsterdam, Netherlands)|December 30, 2019
Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patientsMaria Lucia Reale, Rita Chiari, Marcello Tiseo, et al.
Lancet (London, England)|November 6, 2023
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trialQuincy Chu, Francesco Perrone, Laurent Greillier, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 25, 2023
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, et al.
The Oncologist|December 24, 2025
Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥50%: real-world data from the italian ATLAS registryFrancesco Passiglia, Maria Lucia Reale, Giulia Pasello, et al.
Cancer|May 30, 2026
Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS RegistryFrancesco Passiglia, Antonio Passaro, Eleonora Gariazzo, et al.
Pageof 10